Latest Biotech News

Zag Bio emerged from stealth with $80 million in financing and a platform that aims to induce immune tolerance by delivering bifunctional antibodies to the thymus, the organ that produces...

Hemab Therapeutics closed a $157 million financing to advance a portfolio of programs addressing rare coagulation disorders, including plans to start a pivotal trial of sutacimig in Glanzmann...

BridgeBio reported an encouraging Phase 3 interim readout for ribitol in limb‑girdle muscular dystrophy type 2I/R9 and said it will meet with the FDA to discuss regulatory plans and potential...

Zenas Biopharma reported MoonStone phase‑2 data showing obexelimab, a bifunctional monoclonal antibody, produced a 95% reduction in new gadolinium‑enhancing brain lesions at 12 weeks in relapsing...

GeneDx announced a commercial push into the general pediatrics market, hiring sales teams and streamlining ordering to capture demand after the American Academy of Pediatrics recommended...

Novartis agreed to acquire Avidity Biosciences for about $12 billion, securing three late-stage antibody-oligonucleotide conjugate (AOC) programs targeting neuromuscular diseases and a delivery...

Intellia Therapeutics paused enrollment and dosing in two late‑stage clinical trials of its in vivo CRISPR candidate for transthyretin amyloidosis after a study volunteer was hospitalized with...

GSK licensed global rights to Empirico’s EMP‑012, an inhaled siRNA in Phase 1 for chronic obstructive pulmonary disease (COPD), paying $85 million upfront with up to ~$745 million in potential...

Eli Lilly announced a partnership with Nvidia to build what the companies describe as the most powerful supercomputer operated by a pharmaceutical company, intended to train large AI models for...

Zenas Biopharma reported Phase 2 MoonStone trial results showing obexelimab, a bifunctional monoclonal antibody, reduced new gadolinium‑enhancing brain lesions by 95% over 12 weeks versus placebo...

Electra Therapeutics raised $183 million in an oversubscribed Series C to support a global pivotal program for ELA026, its monoclonal antibody targeting SIRP receptors for secondary hemophagocytic...

Hemab Therapeutics closed a $157 million financing to advance multiple programs for bleeding disorders, including a pivotal trial planned for sutacimig in Glanzmann thrombasthenia and an...

GeneDx reported Q3 revenue up 52% year‑over‑year, driven by exome and genome test growth, and announced a commercial build‑out targeting the general pediatrics market. The company plans to nearly...

Verily integrated Nvidia’s GPU‑accelerated libraries and Blackwell/Hopper GPUs into its Pre precision health research platform to speed genomic and multiomics analyses for researchers, including...

Co‑Diagnostics priced a $7 million direct offering to institutional investors to fund working capital and corporate purposes, and the company also established a joint venture with Arabian Eagle...

Novartis announced an agreement to acquire Avidity Biosciences for roughly $12 billion, adding three late-stage antibody‑oligonucleotide conjugate (AOC) programs aimed at neuromuscular diseases....

Intellia Therapeutics paused enrollment and dosing in two late‑stage trials of its CRISPR candidate nex‑z after a study volunteer was hospitalized with severe liver injury. The company moved...

Takeda Pharmaceutical agreed to codevelop and commercialize up to three immuno‑oncology (I‑O) and antibody‑drug conjugate (ADC) candidates from Innovent Biologics in a deal valued at up to $11.4...

BridgeBio reported positive interim Phase 3 data for BBP‑418 in limb‑girdle muscular dystrophy type 2I/R9, meeting prespecified thresholds and prompting the company to seek discussions with the...

Zenas Biopharma reported that obexelimab, a bifunctional monoclonal antibody, produced a 95% reduction in new gadolinium‑enhancing T1 brain lesions at 12 weeks in the Phase 2 MoonStone study in...